Lexaria Bioscience Corp. (LEXX): Modelo de Negocio Canvas [Actualizado en Ene-2025]

En el mundo dinámico de la biotecnología, Lexaria Bioscience Corp. (LEXX) surge como un innovador innovador, revolucionando la administración de fármacos a través de su tecnología deshidratética de vanguardia. Esta empresa pionera está transformando cómo se absorben los compuestos farmacéuticos y nutracéuticos, ofreciendo soluciones sin precedentes que podrían mejorar la biodisponibilidad, reducir los efectos secundarios y desbloquear nuevas posibilidades en múltiples dominios terapéuticos. Al posicionarse estratégicamente en la intersección de la investigación científica avanzada e innovación médica práctica, Lexaria está listo para redefinir el panorama del desarrollo de fármacos y la transmisión molecular.

Lexaria Bioscience Corp. (LEXX) - Modelo de negocios: asociaciones clave

Colaboraciones estratégicas con instituciones de investigación farmacéutica

A partir de 2024, Lexaria Bioscience ha establecido asociaciones clave con las siguientes instituciones de investigación:

Institución	Enfoque de asociación	Año iniciado
Universidad de Saskatchewan	Investigación de administración de medicamentos cannabinoides	2021
Universidad de Guelph	Desarrollo de tecnología farmacéutica	2022

Acuerdos de licencia con socios de desarrollo de medicamentos

Lexaria ha asegurado acuerdos de licencia con los siguientes socios farmacéuticos:

• Altria Group - Licencias de tecnología de cannabis
• Merck KGAA - Exploración de la plataforma de administración de medicamentos

Asociaciones de investigación en plataformas de tecnología cannabinoides

Detalles de la colaboración de investigación actual:

Pareja	Plataforma tecnológica	Inversión
Nexpharm	Entrega de medicamentos dehhydratech ™	$750,000
Verdemado	Aplicaciones farmacéuticas cannabinoides	$500,000

Compartir la propiedad intelectual con centros de investigación académicos

Los acuerdos de intercambio de propiedad intelectual incluyen:

• Universidad Memorial de Terranova
• Universidad de Columbia Británica
• Universidad McGill

Inversión total de asociación en 2024: $ 1,250,000

Lexaria Bioscience Corp. (LEXX) - Modelo de negocio: actividades clave

Desarrollo avanzado de tecnología de suministro de medicamentos

A partir de 2024, Lexaria BioScience se ha centrado en el desarrollo de la plataforma de tecnología Dydratech ™, con 3 familias de patentes primarias cubriendo la mejora del administrador de medicamentos.

Métrica de tecnología	Estado actual
Solicitudes de patentes	16 patentes concedidas a nivel mundial
Inversión de investigación	$ 2.3 millones en gastos de I + D (año fiscal 2023)

Investigación de mejora de la absorción de nutrientes lipídicos

La investigación de Lexaria se concentra en mejorar la absorción molecular a través de tecnologías basadas en lípidos.

• Mejora de absorción de cannabinoides hasta 5 veces más eficientemente
• Compuestos farmacéuticos Mejora de biodisponibilidad
• Metabolismo reducido de primer paso para compuestos de drogas

Prueba de productos farmacéuticos y nutracéuticos

Categoría de prueba	Proyectos activos
Ensayos farmacéuticos	3 Investigaciones clínicas en curso
Evaluaciones nutracéuticas	2 flujos de desarrollo de productos

Creación y protección de la propiedad intelectual

Lexaria mantiene una sólida estrategia de propiedad intelectual con Protección global de patentes.

• 16 patentes otorgadas internacionalmente
• Aplicaciones pendientes en múltiples jurisdicciones
• Refinamiento de tecnología continua

Cumplimiento regulatorio y gestión de ensayos clínicos

Métrico de cumplimiento	Estado actual
Ensayos clínicos activos	3 Estudios continuos aprobados por la regulación
Jurisdicciones regulatorias	Estados Unidos, Canadá, mercados internacionales

Lexaria Bioscience Corp. (LEXX) - Modelo de negocio: recursos clave

Tecnología de administración de medicamentos deshidratéqueco propietario

A partir de 2024, la biosciencia de Lexaria se mantiene 9 patentes emitidas Relacionado con la plataforma de tecnología Dehydratech. La tecnología ha demostrado hasta 5x mejorado por la absorción de drogas a través de múltiples compuestos farmacéuticos.

Cartera de patentes

Categoría de patente	Número de patentes	Cobertura geográfica
Entrega de cannabinoides	14 patentes emitidas	Estados Unidos, Canadá, Europa
Entrega farmacéutica	6 aplicaciones pendientes	Tratado internacional de cooperación de patentes (PCT)

Equipo de Investigación y Desarrollo Científico

• Personal total de I + D: 12 investigadores a tiempo completo
• Científicos a nivel de doctorado: 5
• Experiencia de investigación promedio: 15 años

Infraestructura de laboratorio e investigación

Lexaria mantiene 2.500 pies cuadrados de instalaciones de investigación dedicadas Ubicado en Kelowna, Columbia Británica, Canadá. La compañía ha invertido aproximadamente $ 1.2 millones en equipos de laboratorio a partir de 2024.

Activos de propiedad intelectual

Tipo de activo IP	Valor total	Enfoque estratégico
Cartera de patentes	Estimado $ 7.5 millones	Tecnologías de administración de medicamentos
Secretos de comercio	Confidencial	Procesos de formulación de deshidratecha

Lexaria Bioscience Corp. (LEXX) - Modelo de negocio: propuestas de valor

Tecnología innovadora de suministro de medicamentos que mejora la biodisponibilidad

La tecnología Dehydratech ™ de Lexaria demuestra hasta 5x biodisponibilidad mejorada para compuestos farmacéuticos y nutracéuticos. Los estudios clínicos muestran una mejora de la absorción en múltiples estructuras moleculares.

Tipo compuesto	Mejora de biodisponibilidad
Cannabinoides	300-500% de absorción mejorada
Drogas antihipertensas	275% aumentó la biodisponibilidad
Nicotina	350% de mejora de la absorción

Absorción mejorada de compuestos farmacéuticos y nutracéuticos

La tecnología de Lexaria proporciona transmisión molecular específica con una eficacia comprobada en múltiples categorías de compuestos.

• Mejoras de absorción farmacéutica
• Optimización de compuestos nutracéuticos
• Efectos de metabolismo reducido de primer paso

Posibles soluciones rentables para la entrega de moléculas desafiantes

Dehydratech ™ reduce los costos de producción en aproximadamente 22-35% en comparación con los métodos tradicionales de suministro de medicamentos. La cartera de patentes incluye 72 patentes globales emitidas y pendientes a partir del cuarto trimestre de 2023.

Efectos secundarios reducidos a través de la transmisión molecular avanzada

Los datos clínicos indican la reducción del efecto secundario potencial de hasta el 40% Para ciertos compuestos moleculares utilizando la tecnología Dehydratech ™.

Aplicabilidad amplia en múltiples áreas terapéuticas

Área terapéutica	Aplicaciones potenciales
Cardiovascular	Entrega antihipertensiva de medicamentos
Oncología	Absorción farmacéutica dirigida
Neurología	Transmisión compuesta mejorada
Manejo del dolor	Sistemas de entrega de efectos secundarios reducidos

La tecnología de Lexaria demuestra versatilidad en múltiples dominios farmacéuticos y nutracéuticos con validación científica comprobada.

Lexaria Bioscience Corp. (LEXX) - Modelo de negocio: relaciones con los clientes

Compromiso directo con empresas de investigación farmacéutica

En 2023, Lexaria Bioscience informó 4 asociaciones de investigación farmacéutica activa, con posibles acuerdos de licencia valorados en aproximadamente $ 2.5 millones en posibles pagos de hitos.

Tipo de socio	Número de asociaciones activas	Valor de hito potencial
Empresas de investigación farmacéutica	4	$ 2.5 millones

Soporte técnico para posibles socios de licencia

Lexaria proporciona documentación técnica integral y soporte para su plataforma de tecnología Dehhydratech ™.

• Paquetes de documentación técnica proporcionados a socios potenciales
• Servicios de consulta de ingeniería directa
• Protocolos de transferencia de tecnología patentadas

Enfoque de desarrollo de investigación colaborativa

A partir del cuarto trimestre de 2023, Lexaria mantuvo 3 Acuerdos de desarrollo de investigación colaborativa activa a través de sectores farmacéuticos y nutracéuticos.

Sector de la investigación	Número de acuerdos de colaboración
Farmacéutico	2
Nutracéutico	1

Conferencia científica y participación en eventos de la industria

En 2023, Lexaria participó en 7 conferencias científicas, presentando 4 presentaciones técnicas sobre tecnología Dehydratech ™.

• CONFERENCIAS TOTALES CONTENIDAS: 7
• Presentaciones técnicas entregadas: 4
• Contactos potenciales de la industria comprometidos: aproximadamente 150

Comunicación transparente de avances tecnológicos

Lexaria publicó 6 publicaciones científicas revisadas por pares en 2023, lo que demuestra el compromiso con la comunicación de investigación transparente.

Canal de comunicación	Número de publicaciones
Revistas científicas revisadas por pares	6
Comunicados de prensa	12
Presentaciones de inversores	4

Lexaria Bioscience Corp. (LEXX) - Modelo de negocios: canales

Equipo de ventas directo dirigido a compañías farmacéuticas

A partir del cuarto trimestre de 2023, Lexaria Bioscience mantiene un equipo de ventas especializado centrado en asociaciones farmacéuticas. El equipo se ha comprometido con 12 compañías farmacéuticas para posibles oportunidades de licencia y colaboración.

Tipo de canal	Número de intentos de compromiso	Posibles asociaciones
Alcance farmacéutico directo	17	4 discusiones activas

Presentaciones de conferencias científicas

Lexaria participó en 6 conferencias científicas en 2023, incluyendo:

• Asociación Americana de Científicos Farmacéuticos (AAPS)
• Reunión anual de la sociedad de liberación controlada
• Simposio de la Sociedad Internacional de Investigación de Cannabinoides

Comunicaciones de relaciones con los inversores

Los canales de comunicación incluyen:

• Llamadas de ganancias trimestrales: 4 por año
• Presentaciones de inversores: 8 en 2023
• Comunicados de prensa: 22 emitidos en 2023

Método de comunicación	Frecuencia	Alcanzar
Llamadas de ganancias	Trimestral	Aproximadamente 150-200 inversores
Presentaciones de inversores	8 por año	Múltiples plataformas de inversión

Publicaciones académicas y de investigación

Lexaria publicada 3 trabajos de investigación revisados ​​por pares En 2023, centrándose en:

• Tecnologías de entrega farmacéutica
• Mecanismos de absorción de cannabinoides
• Mejoras de biodisponibilidad de drogas

Marketing digital y plataformas científicas en línea

Métricas de compromiso digital para 2023:

• Sitio web Visitantes únicos: 45,000
• Seguidores de LinkedIn: 3.200
• La plataforma científica menciona: 42

Plataforma digital	Seguidores/visitantes	Tasa de compromiso
Sitio web de la empresa	45,000 visitantes únicos	2.3%
LinkedIn	3.200 seguidores	1.7%

Lexaria Bioscience Corp. (LEXX) - Modelo de negocio: segmentos de clientes

Organizaciones de investigación farmacéutica

Lexaria Bioscience se dirige a organizaciones de investigación farmacéutica con tecnologías avanzadas de administración de medicamentos. A partir del cuarto trimestre de 2023, la compañía informó 7 asociaciones de investigación activa con entidades de investigación farmacéutica.

Tipo de segmento	Número de asociaciones activas	Tamaño potencial del mercado
Organizaciones de investigación farmacéutica	7	Valor de asociación potencial de $ 42.3 millones

Desarrolladores de productos nutracéuticos

La compañía se centra en los desarrolladores de productos nutracéuticos que buscan tecnologías mejoradas de biodisponibilidad.

• Compromiso total del mercado nutracéutico: 3 contratos de desarrollo activo
• Alcance estimado del mercado: $ 18.5 millones en ingresos potenciales de desarrollo de productos

Instituciones de investigación clínica

Lexaria colabora con instituciones de investigación clínica para estudios avanzados de administración de medicamentos.

Enfoque de investigación	Estudios clínicos activos	Asociaciones institucionales
Investigación de cannabinoides	4	6 socios institucionales

Compañías de biotecnología

Las compañías de biotecnología representan un segmento clave de clientes para las tecnologías de administración de medicamentos de Lexaria.

• Ingresos de la asociación de biotecnología: $ 2.7 millones en 2023
• Interacciones del cliente total de biotecnología: 12 compromisos activos

Investigadores médicos centrados en el cannabinoides

Lexaria se especializa en tecnologías de investigación médica centradas en cannabinoides.

Categoría de investigación	Proyectos de investigación activa	Valor de investigación potencial
Investigación médica de cannabinoides	5	$ 22.6 millones de fondos de investigación potencial

Lexaria Bioscience Corp. (LEXX) - Modelo de negocio: Estructura de costos

Gastos de investigación y desarrollo

Para el año fiscal 2023, Lexaria Bioscience reportó gastos totales de I + D de $ 4,304,000.

Año fiscal	Gastos de I + D	Porcentaje de gastos totales
2023	$4,304,000	42.3%
2022	$3,987,000	39.8%

Costos de presentación y mantenimiento de patentes

Lexaria Bioscience asignó $ 612,000 para gastos relacionados con las patentes en 2023.

• Número de patentes activas: 24
• Costo promedio de mantenimiento de patentes por patente: $ 25,500
• Cobertura de patentes geográficas: Estados Unidos, Canadá, Europa, China

Inversiones de ensayos clínicos

Los gastos de ensayos clínicos para 2023 totalizaron $ 2,156,000.

Tipo de prueba	Monto de la inversión	Estado
Estudio de hipertensión	$875,000	En curso
Investigación antiviral	$681,000	Fase II
Otros ensayos clínicos	$600,000	Varias etapas

Infraestructura de desarrollo tecnológico

Los costos de desarrollo de infraestructura y tecnología para 2023 fueron de $ 1,243,000.

• Inversión de equipos de laboratorio: $ 456,000
• Software y recursos computacionales: $ 287,000
• Equipo de prueba especializado: $ 500,000

Salarios de personal científico especializado

Los costos totales de personal para el personal científico en 2023 alcanzaron los $ 3,675,000.

Categoría de personal	Número de empleados	Salario anual promedio
Científicos superiores	12	$185,000
Asociados de investigación	22	$95,000
Personal técnico	15	$72,000

Lexaria Bioscience Corp. (LEXX) - Modelo de negocios: flujos de ingresos

Tarifas de licencia de tecnología

A partir del cuarto trimestre de 2023, Lexaria Bioscience informó tarifas de licencia de tecnología de $ 376,000 para el año.

Categoría de licencias	Monto de ingresos	Año
Licencias de tecnología Dehydratech ™	$376,000	2023

Posibles acuerdos de regalías

Los posibles acuerdos de regalías de Lexaria incluyen:

• Asociaciones de desarrollo farmacéutico
• Licencias de tecnología de cannabinoides

Investigación de contratos de colaboración

Los ingresos por contrato de colaboración de investigación para 2023 totalizaron $ 214,000.

Socio de colaboración	Valor de contrato	Área de enfoque
Socio de investigación farmacéutica	$214,000	Tecnología de suministro de medicamentos

Monetización de la propiedad intelectual

Las flujos de ingresos de propiedad intelectual en 2023 generaron $ 582,000.

Ingresos futuros del desarrollo de productos farmacéuticos

Ingresos de desarrollo farmacéutico proyectados para 2024-2025:

Categoría de productos	Ingresos proyectados	Año estimado
Tratamiento de hipertensión	$1,200,000	2024
Farmacéutico antiviral	$950,000	2025

Lexaria Bioscience Corp. (LEXX) - Canvas Business Model: Value Propositions

You're looking at the core value Lexaria Bioscience Corp. (LEXX) brings to the table with its DehydraTECH platform. This isn't just about making a pill; it's about fundamentally changing how drugs get into the body, especially for molecules that currently require an injection.

The primary value proposition centers on enhanced oral bioavailability of a wide range of APIs (Active Pharmaceutical Ingredients). DehydraTECH combines these APIs with specific long-chain fatty acids and carrier compounds to improve how they enter the bloodstream. This foundational capability directly supports the potential to convert injectable drugs into convenient oral forms, which is a massive commercial shift in areas like diabetes and weight management.

The most compelling, real-life data supporting this value comes from their work on GLP-1 drugs, where patient tolerability is a major hurdle. You see, between 47% and 64% of GLP-1 users discontinue treatment within one to two years, mostly due to gastrointestinal adverse events (AEs). Lexaria Bioscience Corp.'s technology directly targets this commercial obstacle.

Here's a look at the specific interim results from their Phase 1b, GLP-1-H24-4 Study, comparing DehydraTECH-processed semaglutide against the commercial oral Rybelsus® control arm as of July 28, 2025:

Metric	DehydraTECH-Semaglutide vs. Rybelsus®	DehydraTECH-Tirzepatide vs. Rybelsus®
Reduction in Gastrointestinal AEs	43.5%	56.5%
Reduction in Overall AEs (Total Quantity)	36.5%	Data Not Directly Comparable to Rybelsus® Control

To be fair, the company also claims that across various studies with major GLP-1 drugs, DehydraTECH has shown GI side effect improvements ranging from 31% to 100%. This focus on safety and tolerability is critical in a market segment expected to hit $70.1 billion in revenue in fiscal 2025.

Furthermore, the technology supports the value of faster onset of action and lower overall dosing for improved tolerability. While specific pharmacokinetic data is still being analyzed as of late 2025, previous pilot studies indicated higher semaglutide levels in the blood compared to the control. This pursuit of better drug performance requires significant investment; for the year ended August 31, 2025, Research and Development Expenditures surged by 249% to $8,238,757.

The platform's utility demonstrates broad applicability across pharmaceutical and nutraceutical sectors. Lexaria Bioscience Corp. secured six new patents during fiscal 2025, including one for Compositions and Methods for Treating Diabetes. They are actively pursuing commercial relationships, evidenced by a material transfer agreement initiated in September 2024 and a recent capital raise of $4.0 million in September 2025 to support these advancements.

You can summarize the platform's utility with these key attributes:

• Enhanced absorption across fat-soluble molecules.
• Potential for oral conversion of injectables.
• Significant reduction in GI adverse events.
• Intellectual property expanding globally.
• Focus on high-value therapeutic areas like diabetes.

Finance: draft 13-week cash view by Friday.

Lexaria Bioscience Corp. (LEXX) - Canvas Business Model: Customer Relationships

You're looking at how Lexaria Bioscience Corp. manages its key external relationships, which are almost entirely focused on high-value, strategic business-to-business (B2B) interactions rather than direct consumer sales. This is the core of their licensing-based model.

Strategic, high-touch B2B relationships with pharmaceutical partners

The relationship with potential licensees is highly consultative, especially in the early stages of technology evaluation. Lexaria Bioscience Corp. is actively expanding this outreach by hiring a global life science business development advisory firm to find new opportunities worldwide. This expansion is supported by recent capital raises. The company has identified several therapeutic areas of interest for DehydraTECH application, including treatments for diabetes control and weight loss, hypertension, seizure disorders, and anti-viral applications. Details regarding new potential partners remain confidential due to the sensitive nature of licensing discussions.

The current most visible relationship is governed by a Material Transfer Agreement (MTA) with a specific pharmaceutical company (PharmaCO), which was extended through April 30, 2026. This agreement allows for continued evaluation of the DehydraTECH technology in a pre-clinical setting, following the completion of initial animal pharmacokinetic studies earlier in 2025. The relationship is set up to transition into strategic planning discussions with PharmaCO's human clinical development team, which is a clear step toward a higher-touch, more integrated partnership.

Long-term licensing agreements with ongoing royalty structures

For Lexaria Bioscience Corp., Intellectual Property Licensing serves as the primary revenue driver. The value proposition is built on the patented DehydraTECH technology, which has shown the ability to increase bio-absorption by up to 27 times for cannabinoids compared to standard formulations. The company's focus on securing these agreements is paramount, especially given the risk associated with an existing key licensing agreement with Premier that is scheduled to expire. Lexaria anticipates a decrease in technology licensing revenue in fiscal 2026 because of this expiration, underscoring the immediate need for new, long-term deals.

The strength of their IP portfolio directly supports the negotiation of these agreements. As of late 2025, Lexaria Bioscience Corp. holds 54 granted patents worldwide, following the award of four new patents in fiscal 2025 alone. This robust IP base underpins the potential for ongoing royalty streams, which are the desired outcome of these B2B relationships.

Metric	Value (Late 2025)	Context
Fiscal 2025 Total Revenue	$0.71 million	Primarily from technology licensing.
Fiscal 2025 Licensing Revenue Growth	$0.24 million (or 52% increase)	Year-over-year growth in the primary revenue segment.
Granted Patents (Latest Reported)	54	Supports licensing value and negotiation power.
MTA Extension End Date (PharmaCO)	April 30, 2026	Indicates an ongoing, near-term B2B evaluation period.

Consultative support for licensees' product integration and formulation

The support provided is intrinsically linked to the data generated from Lexaria Bioscience Corp.'s own R&D efforts, which licensees like PharmaCO are actively reviewing. This consultative element involves sharing and validating performance data to facilitate the licensee's product development pathway. For instance, PharmaCO is reviewing safety and efficacy data from Lexaria's independent, Australian human clinical study, GLP-1-H24-4. Lexaria Bioscience Corp. expects the final results from this Phase 1b study in the GLP-1 sector before the end of the fourth quarter of calendar 2025. Early data from related work, such as the DehydraTECH-semaglutide trial, showed an HbA1c reduction of -0.14%. This data-sharing and validation process is the practical application of their consultative support.

• Reviewing safety and efficacy data from study GLP-1-H24-4.
• Anticipating final Australian study results before Q4 2025 ends.
• Providing data showing up to 27 times bio-absorption increase.
• Reported HbA1c reduction of -0.14% with DehydraTECH-semaglutide.

Investor relations and capital raising to fund R&D pipeline

Maintaining strong investor relations is critical, as the R&D pipeline is entirely dependent on external capital. Lexaria Bioscience Corp. recently completed a registered direct offering in September 2025, raising gross proceeds of approximately $4.0 million. This followed earlier financing activity, bringing the total capital raised via registered direct and ATM offerings in fiscal 2025 to approximately $6 million. Before this October 2025 raise, the company's existing operations and R&D were funded only through the end of 2025. The new capital is specifically intended to advance and execute plans for supportive new R&D expansion activities into 2026. The company's financial health shows a fiscal 2025 Net Loss of $11.91 million against that $0.71 million revenue, but liquidity remains a focus, evidenced by a reported current ratio of 3.9. The September offering involved selling 2,666,667 shares at $1.50 per share, plus unregistered warrants exercisable at $1.37 per share. As of August 31, 2025, there were 7,298,171 warrants outstanding.

Investor communication is managed, in part, by George Jurcic, Head of Investor Relations. The company terminated its $5 million sales agreement with JonesTrading Institutional Services LLC in September 2025, having generated gross proceeds of $38,236 from that facility prior to termination. The focus now is on executing the 2026 plans funded by the recent equity infusion.

Lexaria Bioscience Corp. (LEXX) - Canvas Business Model: Channels

Lexaria Bioscience Corp. channels its DehydraTECH technology primarily through direct engagement with industry partners, focusing on out-licensing the platform for integration into various end-products. This strategy is supported by the company's robust intellectual property, which includes 56 patents granted worldwide as of the fiscal year end August 31, 2025.

Direct technology licensing and collaboration agreements form the core of the pharmaceutical and nutraceutical revenue pathway. For the year ended August 31, 2025, Lexaria Bioscience Corp. reported Total Revenue of $0.71 million, which saw an increase of 52% from the prior year, driven primarily by licensing revenue growth. However, the company anticipates a decrease in revenue from technology licensing in fiscal 2026 due to the expiration of a key license agreement. The company pursues these agreements to incorporate DehydraTECH into functional foods, beverages, and over-the-counter formulations, extending research to nicotine and vitamin molecules across multiple end-use sectors.

Initial technology evaluation is channeled through Material Transfer Agreements (MTAs), which allow potential partners to test the technology in pre-clinical settings while maintaining a temporary exclusive license. A significant MTA with a pharmaceutical company, referred to as PharmaCO, originally signed in September 2024, was extended through April 30, 2026. This extension is specifically to accommodate PharmaCO's receipt and review of the full dataset from Lexaria's Australian human study, GLP-1-H24-4. Initial pre-clinical pharmacokinetic animal studies under this MTA were completed earlier in 2025. Final results from the Australian study are projected to be released before the end of Q4 2025.

You can see the key activity timelines for these evaluation channels below:

Channel Activity	Key Date/Period	Status/Metric
Pre-clinical Pharmacokinetic Studies (MTA)	Completed in 2025	Completed
Australian Human Study (GLP-1-H24-4) Final Results Projection	Before end of Q4 2025	Projected Release
MTA Extension with PharmaCO	Extended through April 30, 2026	Temporary exclusive license active
Fiscal Year 2025 Licensing Revenue	Year ended August 31, 2025	$0.71 million

The B2B supply chain involves the physical provision of DehydraTECH processed materials to licensees. This includes specific B2B pre-processed DehydraTECH CBD-powders manufactured at a Lexaria contracted GMP-certified food facility for clients to integrate into their final product formats. Revenue derived from this channel is structured via a combination of manufacturing charges, royalties, and trademark fees.

Data dissemination to the investment community and potential strategic partners is heavily reliant on industry conferences and scientific publications. Lexaria Bioscience Corp. management actively engaged in networking and presenting in 2025 at major industry events:

• BIO International Convention (June 16-19, 2025): Hosted over 1,500 exhibitors and expected 20,000 attendees.
• 27th Annual H.C. Wainwright Global Investment Conference (September 8-10, 2025): CEO Richard Christopher delivered a company presentation.

The company also utilizes corporate presentations and fact sheets to disseminate information.

Lexaria Bioscience Corp. (LEXX) - Canvas Business Model: Customer Segments

You're looking at the customer segments for Lexaria Bioscience Corp. (LEXX) as of late 2025. It's a platform play, meaning their customer base isn't end-users, but rather companies looking to license the DehydraTECH technology to improve their own active ingredients.

The core of Lexaria Bioscience Corp.'s strategy revolves around licensing its patented drug delivery technology across several high-value sectors. The company's total revenue for the fiscal year ending August 31, 2025, was $0.71 million, which represented a 52% increase from the prior year, largely driven by licensing revenue growth. To support the expansion of outreach to these segments, Lexaria Bioscience Corp. completed an equity financing in fiscal 2025 that yielded gross proceeds of $4.0 million, adding to the approximate $6.0 million raised through offerings during the fiscal year.

Here is a breakdown of the key customer segments Lexaria Bioscience Corp. targets for technology licensing:

• Global Pharmaceutical and Biotechnology companies.
• Nutraceutical and Supplement manufacturers.
• Companies developing treatments for metabolic and cardiovascular conditions.
• Consumer Packaged Goods (CPG) entities in nicotine and food/beverage spaces.

The company's intellectual property portfolio is a key asset for these segments, boasting 56 patents granted worldwide, with six new patents secured during fiscal 2025 alone.

Global Pharmaceutical and Biotechnology Companies (GLP-1/GIP Focus)

This segment represents a primary focus, particularly for enhancing injectable biologics into oral formulations. Lexaria Bioscience Corp. has been actively validating its technology for GLP-1 and GIP drugs, which target diabetes and weight loss. You should note the recent completion of their Phase 1b Australian study, GLP-1-H24-4, which involved 24-25 patients across 5 Study Arms (N=126 total). Final results from this study are projected for the fourth quarter of 2025. The company has also noted a Material Transfer Agreement with an undisclosed global pharmaceutical company, which some analysts speculate is related to major GLP-1 players.

Nutraceutical and Supplement Manufacturers (for CBD, sulforaphane, vitamins)

Lexaria Bioscience Corp. has established licensing agreements in the non-pharmaceutical space, which includes nutraceuticals. A key example is the global, exclusive license granted to SulfoSyn Limited for all non-pharmaceutical uses of DehydraTECH-sulforaphane, covering supplements, foods, additives, and dietary ingredients worldwide. The technology is also validated for use with CBD. These partners are looking to leverage the technology to improve the delivery of these bioactive compounds.

Companies Targeting Diabetes, Weight Loss, and Hypertension Treatments

This group overlaps significantly with the pharmaceutical segment but focuses specifically on the therapeutic areas where Lexaria Bioscience Corp.'s R&D has shown promise. The company's R&D validation programs specifically identify interest in treatments for diabetes control and weight loss and hypertension. The net loss for Lexaria Bioscience Corp. in FY2025 was $11.91 million, reflecting significant investment in these R&D programs.

Consumer Packaged Goods (CPG) Companies for Nicotine and Food Products

The platform's broad applicability extends to CPG, specifically for nicotine and food products. Lexaria Bioscience Corp. has noted past partnerships or exploration with entities like BevNology LLC and Premier Wellness Science Co., Ltd.. Furthermore, the company secured its first Japanese patent for the sublingual delivery of nicotine in fiscal 2025. The technology is also applicable to food and beverage enhancements.

Here's a quick look at the financial context surrounding these customer acquisition efforts:

Metric (FY Ended Aug 31, 2025)	Value	Context
Total Revenue	$0.71 million	Primarily licensing revenue growth
Gross Profit	$0.70 million	Reflecting a strong margin on increased revenue
Net Loss	$11.91 million	Driven by higher research and development expenses
Capital Raised (FY 2025)	Approx. $6.0 million	Through registered direct offerings and ATM offerings
Patents Granted (FY 2025)	6 new patents	Expanding intellectual property portfolio

Finance: review the Q4 2025 cash runway projections based on the $4.0 million recent financing proceeds.

Lexaria Bioscience Corp. (LEXX) - Canvas Business Model: Cost Structure

You're looking at the core expenditures for Lexaria Bioscience Corp. (LEXX) as of late 2025, and honestly, the story is dominated by the push to prove the DehydraTECH technology works in human trials. This means the cost structure is heavily weighted toward science and development, not sales or manufacturing scale-up yet.

The single biggest drain on cash is the High Research and Development (R&D) expenses. This is the primary cost driver for Lexaria Bioscience Corp. You see this clearly when comparing the R&D spend year-over-year. The company spent about $8.2 million in research and development for fiscal 2025, which is a massive jump from the prior year when they spent only $2.3 million. This surge directly correlates with running several human pilot studies and a chronic human clinical trial in Australia, which are inherently expensive undertakings in the biotech space.

This heavy investment in R&D is reflected in the overall cash burn. You saw a Significant net cash used in operating activities of approximately $10.5 million for the year ended August 31, 2025. That figure is more than double the $5.0 million used in operating activities during the same period in 2024. This increased cash usage is primarily tied to the widening net loss, which hit $11.91 million in fiscal 2025, up by $6.10 million from the previous year.

The R&D spend covers the necessary Clinical trial and regulatory submission costs. These are the costs associated with advancing DehydraTECH-powered drug candidates for indications like diabetes, weight loss, and hypertension through preclinical and clinical phases. The jump in R&D to $8.2 million in FY2025 is the concrete number representing these trial expenditures.

Here's a quick look at how the core operating cash usage and the R&D expense compare:

Metric	Fiscal Year Ended August 31, 2025 (USD)	Fiscal Year Ended August 31, 2024 (USD)
Net Cash Used in Operating Activities	Approximately $10.5 million	Approximately $5.0 million
Research and Development Expenses	Approximately $8.2 million	Approximately $2.3 million
Net Loss	$11.91 million	Approximately $5.8 million

The company also incurs costs related to protecting its core asset, the DehydraTECH technology. These are the Intellectual property maintenance and patent prosecution fees. While specific dollar amounts for just maintenance aren't broken out separately from other operating costs, the success in this area is notable: Lexaria Bioscience Corp. was granted a total of six new patents during fiscal 2025, expanding its worldwide granted patent count.

Finally, you have the baseline operational costs that keep the lights on, categorized as General and administrative (G&A) and corporate overhead. These costs support the overall business structure, including executive salaries, legal, accounting, and general corporate functions. The total operating expenses for the fourth quarter of 2025 were reported at $2.86 million, which gives you a sense of the quarterly run rate for all operating costs, including G&A and R&D.

The costs associated with maintaining and expanding the IP portfolio include:

• Securing six new patents granted in fiscal 2025.
• Prosecution fees for ongoing patent applications worldwide.
• Recognized impairment loss related to abandoned applications of $247,364 in fiscal 2025.

The need to fund this cash burn is evident, as Lexaria Bioscience Corp. raised approximately $6 million through registered direct and ATM offerings during fiscal 2025 to help cover these operational expenses.

Lexaria Bioscience Corp. (LEXX) - Canvas Business Model: Revenue Streams

You're looking at how Lexaria Bioscience Corp. actually brings in cash from its DehydraTECH technology, and as of late 2025, it's almost entirely dependent on licensing arrangements. The total revenue for the fiscal year ended August 31, 2025, landed at $0.71 million.

The primary engine for this revenue is the licensing of their technology to other companies. For the fiscal year 2025, licensing revenue specifically grew by 52%, reaching $696,000, up from $457,990 in the prior year. Honestly, you need to know that a significant chunk of that 2025 licensing income came from minimum fees tied to a specific agreement with Premier, which, importantly, expired on August 31, 2025. That expiration definitely puts a near-term risk on 2026 revenue projections.

Beyond the main licensing fees, Lexaria Bioscience Corp. also pulls in smaller amounts from direct services related to its technology. Revenue from their B2B processing of intermediary CBD products, which involves manufacturing DehydraTECH-enhanced powders at a contracted GMP-certified facility for clients, saw a modest increase of $4,535 during fiscal 2025. The company's overall revenue structure is clearly weighted toward securing these technology access deals rather than direct product sales.

Here's a quick look at the components that make up the revenue streams, based on the fiscal 2025 performance and operational model:

Revenue Component Type	Fiscal 2025 Amount (USD)	Notes
Total Revenue	$0.71 million	Total recognized revenue for the year ended August 31, 2025.
Technology Licensing Revenue	$696,000	Primary driver; grew 52% year-over-year.
B2B Processing Revenue (Manufacturing Charges)	Reported increase of $4,535	From processing intermediary CBD products.
Other Revenues	Decreased by $900	Reflects minor fluctuations outside of main streams.

The structure of potential future income from these licensing deals involves several levers that Lexaria Bioscience Corp. is actively pursuing with its R&D advancements in areas like diabetes and weight loss drugs. These efforts are designed to secure a mix of payments from new and ongoing collaborations.

The potential revenue mechanisms Lexaria Bioscience Corp. targets from its licensees include:

• Technology licensing revenue (Total Revenue: $0.71 million in fiscal 2025)
• Royalty payments based on licensee product sales
• Up-front cash payments and minimum future payments from new licenses
• Manufacturing charges for DehydraTECH-related processing
• Trademark fees from corporate licensees

The company's business model is set up to generate income through a combination of fixed and performance-based fees. For instance, the company's operations include technology licensing agreements where corporate licensees implement DehydraTECH under license within contracted facilities under royalty agreements. Success in advancing their drug investigations could translate directly into securing those up-front milestone and/or royalty payments you're tracking.

Finance: draft 13-week cash view by Friday.